Glen Eagle Advisors, LLC Karyopharm Therapeutics Inc. Transaction History

Glen Eagle Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Aug 13, 2024	SELL	$5.21 - $8.61 $3,126 - $5,166	-600 Closed	0 $0
Q3 2021 Aug 13, 2024	SELL	$4.45 - $10.63 $445 - $1,063	-100 Reduced 14.29%	600 $3.49 Million
Q2 2021 Aug 13, 2024	SELL	$8.11 - $11.11 $892 - $1,222	-110 Reduced 13.58%	700 $7.22 Million
Q4 2020 Aug 13, 2024	BUY	$14.15 - $17.19 $11,461 - $13,923	810 New	810 $12.5 Million
Q3 2020 Aug 13, 2024	BUY	$14.14 - $19.71 $5,231 - $7,292	370 Added 108.82%	710 $10.4 Million
Q2 2020 Aug 13, 2024	BUY	$16.6 - $25.25 $5,644 - $8,585	340 New	340 $6.44 Million

57.6M

258K

81.2K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $51.1M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.